A rapid, single-reagent, non-separation, non-isotopic immunoassay was developed for determining levels of the nicotine metabolite, cotinine, in urine.
A dose-response relationship exists between the number of cigarettes smoked and the risk of developing smoke-related diseases. 1 This explains the interest in ways of distinguishing between smokers and non-smokers (passive smokers) shown by insurance companies, surgeons and forensic scientists. Suitable methods include measurement of serum thiocyanate and carboxyhaemoglobin concentrations/: 3 and the concentrations of nicotine and cotinine in biological fluids.v" The measurement of urinary cotinine is the preferred approach for several reasons. Firstly, cotinine is only derived from the metabolism of nicotine," whereas carboxyhaemoglobin and thiocyanate levels can be raised due to environmental influences. 2 Secondly, the methods for measuring cotinine are less complex than those for thiocyanate and carboxyhaemoglobin. Thirdly, urine is more convenient to assay than blood. Finally, cotinine has a half-life of between 7 and 40 h,? whereas the half-life of nicotine is less than 30 rnin.l''
There are several methods available for the detection of cotinine concentrations in urine, including chromatographic procedures. However, despite recent developments in highperformance liquid chromatography and gas-Correspondence: M C Hansel, Department of Chemical Pathology, St Bartholomew's Hospital, 48--50Bartholomew Close, London ECIA 7HL, UK. 596 liquid chromatography, these methods are still complex and time consuming, and require sample preparation and large sample volumes." Radioimmunoassar (RIA) are the most widely used technique.P' . 11, 12 being both sensitive and specific, but their use may involve administrative and regulatory complications, and the methods are technically complex, due to the need for a separation step. Also, assays involving tritiated tracer suffer from the inconvenience and cost of liquid scintillation counting, while radioiodinated tracers have a limited shelf-life. This paper describes the development and validation of a single reagent polarisation fluoroimmunoassay (PFIA) for measuring urinary cotinine, based on the increase in signal associated with antibody binding of a fluorescent-labelled antigen. 13 Its use permits a rapid, non-separation assay, with reagents that have a virtually indefinite shelf-life and avoid any biohazard and administrative problems. The assay covers the range of cotinine values found in active smokers and is reliable and robust. 
Materials and methods

MATERIALS
Preparation of cotinine tracer
Trans-4'-carboxycotinine and fluoresceinthiocarbamyl ethylenediamine (FfC-ED) were prepared according to published procedures. 14, IS To 0·5 mL of a mixture of dimethylformamide and pyridine (1/1 by volume) was added 10mg trans-4'-carboxycotinine. This was rotated gently until dissolved, then 10 mg Nhydroxysuccinimide and 30 mg 1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride were added and left for 1 h, rotating gently, to form the active ester. This was added dropwise over a 15-min period to 20 mg of FfC-ED previously dissolved in 0·5 mL of the above solvent.
The reaction mixture was left mixing overnight in the dark and then applied to TLC plates (0,2 mL per plate) and developed with methanol/chloroform (40/60 by volume). The major fluorescent band (Rf=0'57) was scraped from the plate, and the product extracted into methanol (3 mL per plate) and stored at -20°C in the dark until required.
The concentration of the fluorescein-labelled cotinine product was determined spectrophotometrically. IS Preparation of cotinine immunogen ( Fig. 1) Preparation of benzyloxycarbonylglycyl pnitrophenylalanine methyl ester (I). To a solution of dicyclohexyl carbodiimide (1,4 g, 0·0067 mol) in anhydrous dioxan (30 mL) was added benzyloxycarbonylglycine (1,3 g, 0·0069 mol), 16 p-nitrophenyl(-L-)alanine methyl ester hydrochloride (1,5 g, 0·0067 mol)!" and triethylamine (0,4 g, 0·0067 mol). The mixture was stirred at room temperature for 12 h, then filtered and the filtrate evaporated to dryness. The residue was dissolved in ethyl acetate (50 mL) and washed with 0·5 mol/L hydrochloric acid (5 mL), water (10 mL), sodium carbonate solution (50 g/L, 10 mL) and water (10 mL). The solution was dried (magnesium sulphate)
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Preparation of glycyl p-nitrophenylalanine methyl ester (II). The dipeptide (I) from above was treated with 45% hydrogen bromide in glacial acetic acid (10 mL). The orange solution was stirred at room temperature for 1 hand evaporated to dryness to yield the product as the hydrobromide (Rf 0·64 in the above TLC system). The NMR of the product showed no benzylic protons at 5·28 [).
Preparation of cotinine-d'-amidoglycyl-pnitrophenylalanine methyl ester (III). The dipeptide (II) (2,95 g, 0·013 mol), trans-4'carboxycotinine" (2·76 g, 0·013 mol) and . trimethylamine (0· 78 g, 0·013 mol) were added to a solution of dicyclohexyl carbodiimide (2,69 g, 0·013 mol) in anhydrous dioxan (30 mL). The solution was stirred for 12 h at room temperature, then filtered and the solvent removed under reduced pressure. The residue was dissolved in ethyl acetate (50 mL), extracted with 5 mol/L hydrochloric acid (2 X 10 mL) and the aqueous extract then neutralised to litmus with sodium hydroxide (5 mol/L) and the resulting precipitate extracted with chloroform (2 x 25 mL) and the solution evaporated to dryness under vacuum. The product ran as a single spot on silica-gel TLC in methanol (Rf 0·61 compared with the dipeptide 0·73 and trans-4'carboxycotinine 0·47).
Preparation of cotinine-4' -amidoglycyl-paminophenylalanine
methyl ester (IV). Cotinine-dipeptide (III) (0·72 g, 0·00152 mol) was dissolved in methanol and hydrogenated in the presence of Adam's catalyst (100 mg) at room temperature. After removing excess hydrogen, the mixture was filtered and evaporated to dryness. The product gave a positive diazotiza tion test.
Coupling of cotinine derivative to KLH. The product (IV) (50 mg) was diazotised, coupled to KLH (64 mg), and the conjugate isolated using previously described methodsY Anti-cotinine serum Three mature female sheep were immunised with the cotinine immunogen by a previously described protocol. 19 
Assay buffer
The assay diluent buffer was sodium borate (10 mmol/L, pH 9,0) containing bovine gamma globulins (1 gIL) and sodium azide (1 gIL).
Synthetic urine
Urea (22 g), creatinine (1,50 g), sodium chloride (8.25 g), potassium chloride (5·20 g), sodium dihydrogen orthophosphate dihydrate (1·40 g), di-sodium hydrogen orthophosphate dihydrate (1,10 g), sodium azide (1·0 g) and tartrazine (10 mg) were dissolved in 1 L of distilled water and stored at 4°C.
Assay standards
Cotinine was dissolved in synthetic urine to obtain standards with concentrations of 0, 0·5, 1,2,4 and 8 mgIL which were stored at 4°C.
Single reagent
This was prepared by combining tracer (10 nmol/L) and antiserum diluted 1125-fold in assay buffer. The single reagent was stored at 4°C in the dark until required. 
Urine specimens
Analytical recovery
Cotinine at concentrations of 1 and 2 mgIL was added to urine from a known non-smoker with apparent cotinine level of 0·075 mg/L and from two smokers, with cotinine concentrations of 0·9 and 4 mg/L respectively. Analytical recoveries were 107·5±7·3% and 99·5±2·5% (mean ± standard deviation respectively).
Precision
Three pools of selected urine samples were each assayed 20 times in one assay, giving mean results of 0·90, 2·90 and 3·6 mg/L with withinassay coefficients of variation of 4·5, 5·5 and 8·5% respectively. Assay of the same specimens on 10 different days gave between assay coefficients of variation of 5·8, 5·0 and 6·4% respectively.
ANALYTICAL VARIABLES
Sensitivity
The zero standard (assay buffer) was measured in 20 replicates and the mean and standard deviation of the polarisation response was calculated to determine sensitivity according to Rodbard's method.i" The minimum detectable concentration of cotinine at the 95% confidence level was 0·1 mgIL. STANDARD CURVE Figure 3 shows the standard curve obtained in the cotinine single-reagent PFIA system, which covers the range of cotinine values found in active smokers.
nmoUL) and antiserum (I125-fold diluted) and the fall in polarisation readings measured at time intervals.P The data were analysed in terms of dissociation of antibody populations with differing dissociation half-lives.P The halflife for the initial rapid fall in polarisation readings was estimated to be 110 s (Fig. 2) . Thus, a half-hour incubation in the singlereagent cotinine PFIA is more than adequate.
ACCELERATED STABILITY
The single reagent was kept at 37°C and standard curves measured one week and a fortnight later -expected to be equivalent to one year and two years at 4°C respectively.P The polarisation values were all similar. In contrast, when the antiserum and tracer were kept separately at 37°C there was a marked deterioration in assay performance. room temperature in duplicate. To 1·5 mL of single reagent was added 10 I-iL of assay standard or urine sample. The tubes were then mixed and left to incubate for 30 min before reading fluorescence polarisation. 
Discussion
An understanding of the dissociation kinetics of antibody and tracer enables the development of single-reagent immunoassays.P Thus, when the dissociation of tracer from antibody is rapid, a single reagent consisting of pre-equilibrated antibody and tracer may be used. 2 {}-22 The polarisation half-life was 110 s for the fast dissociating component of the cotinine singlereagent PFIA system; thus, a 3D-minincubation period was more than adequate. Should a faster assay be required, a higher incubation temperature would shorten the incubation time. 22 The cotinine single-reagent system gave comparable results even after 2 weeks at 37°C, which implies 2 years stability at 4°c. 21 In URINARY COTININE KINETICS A healthy female staff member who was a moderate smoker (about 10 cigarettes per day) had decided to give up the habit. A random urine specimen was taken the day before she stopped smoking and another was taken 2 h after her last cigarette. Morning and afternoon specimens were taken each day thereafter in order to monitor the drop in the urinary cotinine concentration (Fig. 5 ). smoking leading to measurable cotinine levels and interfering fluorescent components of urine itself.
From these 30 urines and others used in the correlation study, a cut-off point of less than 1·0 mgIL urinary cotinine was established for non-smokers, while a result greater than this indicated an active smoker. Thirty urine specimens were collected from non-smoking members of our laboratory staff and assayed. The mean and standard deviation of the polarisation response values were calculated. The mean response corresponded to an apparent cotinine concentration of 0·12 mgIL and the mean response less three standard deviations corresponded to an apparent concentration of 0·45 mg/L, The apparent cotinine concentration in the non-smokers was comparatively high due to a combination of passive Sixty-nine urine samples from both smokers and non-smokers which had been previously assayed by RIA 6 were assayed by PFIA. For the 39 specimens with measurable cotinine concentrations, the correlation coefficient (r) was 0·92 where PFIA (y) and RIA (x) were related by the regression line y=0·90x-Q·04 (Fig. 4) . The 27 non-smokers' specimens all gave cotinine concentrations less than O· 7 mgIL. Samples from regular active smokers all gave cotinine concentrations of greater than 1 mg/L,
Specificity
Nicotine showed less than 0·1 % cross reactivity at the 1 gIL level, while of the available metabolites nicotine 1-N-oxide, isonicotinic acid, pyridylacetic acid, nicotinic acid and nicotinamide all showed less than 0·1 % cross reactivity when tested at the 100 mg/L level.
comparison, when tracer and antibody were kept separately at 37°C for 2 weeks, the results showed a marked deterioration. It has been suggested that antibody binding may stabilise or protect the tracer. 22 Although non-separation immunoassays are technically convenient, they are susceptible to interfering factors. To avoid them, small sample and standard volumes (10 ul.) were used in the urinary cotinine PFIA.
It has been reported previously that there is an overlap in the levels of heavy passive smokers and of light or occasional smokers.P: 7 This was the case in the present study and, to avoid giving a false positive result for a nonsmoker, a cut-off level of 1·0 mgIL was chosen. This cut-off was also above the apparent cotinine concentrations that might result from urine interference, as determined with nonsmokers' samples. As a result, all non-smokers (including passive smokers) were readily segregated from active smokers.
Cotinine concentrations were followed for a number of days after a regular active smoker gave up smoking. After one day, cotinine concentrations were still typical of an active smoker, after 2 days of a heavy passive smoker or a light smoker, and by the third day, the cotinine concentrations had dropped to those expected of a non-smoker (Fig. 5 ).
The present assay was designed to differentiate between active smokers and non-smokers (including passive smokers) and also to provide values for cotinine concentrations over the range of the standard curve ( Fig. 3 ). If an assay to detect lower concentrations of cotinine were re~uired, a separation fluorimmunoassay" L. 19 could be developed using anticotinine serum coupled to solid-phase particles and the same fluorescein-labelled cotinine. The separation step would enable the removal of sample components that interfere with the fluorescence end-point measurement, and therefore allow larger samp.le (urine or serum) volumes to be employed. 5 cotinine immunogen, and to Dr G A Ellard of the National Institute for Medical Research for the materials employed in cross-reaction studies.
